EDITORIALS

Ghost Writers in the Sky

Bruce A. Chabner
The Oncologist 2009; 14: 199-200; doi:10.1634/theoncologist.2009-0031
[Full Text] [PDF]  

SUMMARY: This editorial outlines The Oncologist's policy on the use of ghost writers for manuscripts published in this journal.

Ductal Intraepithelial Neoplasia: Postsurgical Outcome for 1,267 Women Cared for in One Single Institution over 10 Years

Aliana Guerrieri-Gonzaga, Edoardo Botteri, Nicole Rotmensz, Fabio Bassi, Mattia Intra, Davide Serrano, Giuseppe Renne, Alberto Luini, Massimiliano Cazzaniga, Aaron Goldhirsch, Marco Colleoni, Giuseppe Viale, Giovanni Ivaldi, Vincenzo Bagnardi, Matteo Lazzeroni, Andrea Decensi, Umberto Veronesi, Bernardo Bonanni
The Oncologist 2009; 14: 201-212; doi:10.1634/theoncologist.2008-0203
[Abstract] [Full Text] [PDF]  

SUMMARY: This study analyzed risk factors and treatment outcome in a large series of women with ductal intraepithelial neoplasia. Subsequent breast cancer events were more frequent in young patients, radiotherapy was associated with a lower incidence of such events, and low-dose tamoxifen was associated with a lower incidence of such events in patients with estrogen receptor–positive disease when human epidermal growth factor receptor 2 was not overexpressed.

Commentary: Antioxidants for Cancer: New Tricks for an Old Dog?

Nima Sharifi
The Oncologist 2009; 14: 213-215; doi:10.1634/theoncologist.2008-0219
[Abstract] [Full Text] [PDF]  

SUMMARY: This article presents emerging evidence on the molecular effects of antioxidants on tumor cells and evidence that the route of administration of antioxidants in earlier clinical trials for cancer could not achieve pharmacologically effective levels to call for a re-examination of the current evidence and further study of the role of antioxidants in cancer therapy.

Understanding the Relationship Between Age and Thyroid Cancer

Megan R. Haymart
The Oncologist 2009; 14: 216-221; doi:10.1634/theoncologist.2008-0194
[Abstract] [Full Text] [PDF]  

SUMMARY: This article explores the characteristics of the normal thyroid and thyroid cancer that are age dependent. It then provides theories for the relationship between advanced age and poor prognosis, in addition to treatment options tailored to age at diagnosis.

Acute Myelogenous Leukemia in Older Adults

Heidi D. Klepin, Lodovico Balducci
The Oncologist 2009; 14: 222-232; doi:10.1634/theoncologist.2008-0224
[Abstract] [Full Text] [PDF]  

SUMMARY: This study investigates the treatments and outcomes of older adults with acute myelogenous leukemia. The study finds that older adults with favorable tumor biology, good functional status, and minimal comorbidity can benefit from standard induction chemotherapy and recommends that treatment decisions be individualized after careful consideration of tumor biology and patient characteristics.

Thyroid Storm After Intensity-Modulated Radiation Therapy: A Case Report and Discussion

Roberto Diaz, Marc D. Blakey, Patrick B. Murphy, A. Keith Cryar, Anthony J. Cmelak
The Oncologist 2009; 14: 233-239; doi:10.1634/theoncologist.2008-0156
[Abstract] [Full Text] [PDF]  

SUMMARY: This article presents a case of severe thyrotoxicosis developing in a patient with locally advanced squamous cell carcinoma of the base of tongue treated with induction chemotherapy followed by intensity-modulated radiation therapy, and warns physicians of the difficulty in diagnosing this condition because of the significant overlap between the signs and symptoms of severe thyrotoxicosis and the expected toxicities of cancer therapy.

Immunotherapy of Acute Myeloid Leukemia: Current Approaches

Evelien L.J.M. Smits, Zwi N. Berneman, Viggo F.I. Van Tendeloo
The Oncologist 2009; 14: 240-252; doi:10.1634/theoncologist.2008-0165
[Abstract] [Full Text] [PDF]  

SUMMARY: In this review, an overview is provided of both active and passive immunotherapy strategies that are under investigation or in use for the treatment of AML. For each strategy, a critical view on the state of the art is given and future perspectives are discussed.

The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies

Giorgio Scagliotti, Nasser Hanna, Frank Fossella, Katherine Sugarman, Johannes Blatter, Patrick Peterson, Lorinda Simms, Frances A. Shepherd
The Oncologist 2009; 14: 253-263; doi:10.1634/theoncologist.2008-0232
[Abstract] [Full Text] [PDF]  

SUMMARY: This review of two large, randomized, phase III studies of pemetrexed treatment for non-small cell lung cancer provides evidence of a significant and consistent interaction between non-small cell cancer histology and a pemetrexed treatment effect, confirming a treatment advantage for pemetrexed in patients with nonsquamous histology.

Bone-Resorbing Cells in Multiple Myeloma: Osteoclasts, Myeloma Cell Polykaryons, or Both?

Franco Silvestris, Sabino Ciavarella, Monica De Matteo, Marco Tucci, Franco Dammacco
The Oncologist 2009; 14: 264-275; doi:10.1634/theoncologist.2008-0087
[Abstract] [Full Text] [PDF]  

SUMMARY: This review addresses the main evidence provided by the authors' studies and the literature for the view that malignant plasma cells exert osteoclast-like activity.

Myeloma Bone Disease: Recent Advances in Biology, Diagnosis, and Treatment

Orhan Sezer
The Oncologist 2009; 14: 276-283; doi:10.1634/theoncologist.2009-0003
[Abstract] [Full Text] [PDF]  

SUMMARY: This review focuses on recent advances in our understanding of the biology of osteoclast activation and osteoblast inhibition in multiple myeloma, diagnostic standards, and recent progress in treatment options for myeloma bone disease.

FDA Review of a Panitumumab (Vectibix^TM) Clinical Trial for First-Line Treatment of Metastatic Colorectal Cancer

Ruthann M. Giusti, Martin H. Cohen, Patricia Keegan, Richard Pazdur
The Oncologist 2009; 14: 284-290; doi:10.1634/theoncologist.2008-0254
[Abstract] [Full Text] [PDF]  

SUMMARY: The manuscript reports on a second panitumumab study for first-line treatment of patients with metastatic colorectal cancer to be included in the panitumumab package insert.

Search for Evidence-Based Approaches for the Prevention and Palliation of Hand–Foot Skin Reaction (HFSR) Caused by the Multikinase Inhibitors (MKIs)

Roger Anderson, Aminah Jatoi, Caroline Robert, Laura S. Wood, Karen N. Keating, Mario E. Lacouture
The Oncologist 2009; 14: 291-302; doi:10.1634/theoncologist.2008-0237
[Abstract] [Full Text] [PDF]  

SUMMARY: This study systematically reviews the literature on the prevention and palliation of multikinase inhibitor–associated hand–foot skin reaction to identify areas for further clinical study and to provide a foundation for evidence-based guidelines for hand–foot skin reaction management.

A Drug-Related Phototoxic Reaction and Its Possible Relationship to a Radiation-Induced Skin Reaction

George A. Dawson, Sam I. Brown, Lillian Tellefsen
The Oncologist 2009; 14: 303-306; doi:10.1634/theoncologist.2008-0277
[Full Text] [PDF]  

SUMMARY: Reported is a case of an acute atypical radiation-induced dermatologic reaction in a patient with a recent history of two courses of levofloxacin within 90 days prior to starting radiotherapy.

Anti–Epidermal Growth Factor Receptor Monotherapy in the Treatment of Metastatic Colorectal Cancer: Where Are We Today?

Marc Peeters, Tim Price, Jean-Luc Van Laethem
The Oncologist 2009; 14: 307; doi:10.1634/theoncologist.2008-0167erratum
[Full Text] [PDF]  

To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button.